Luminal B tumors are the most frequent molecular subtype in breast cancer of North African women: An immunohistochemical profile study from Morocco

Diagnostic Pathology

Volumn 7, Issue 1, 2012, Pages

  El Fatemi, Hinde ^a   Chahbouni, Sanae ^a   Jayi, Sofia ^a   Moumna, Kaoutar ^a   Melhouf, My A ^a   Bannani, Abdelaziz ^a   Mesbahi, Omar ^a   Amarti, Afaf ^a  

^a HASSAN II UNIVERSITY HOSPITAL   (Morocco)

Author keywords

Antibodies; Breast cancer; Immunohistochemistry; Luminal B subtype; Molecular classification; Staging

Indexed keywords

PARAFFIN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BREAST TUMOR; CARCINOMA; CHEMISTRY; CLASSIFICATION; ETHNOLOGY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; METASTASIS; MIDDLE AGED; MOROCCO; NEGRO; PATHOLOGY; PREDICTIVE VALUE; PREVALENCE; TEACHING HOSPITAL; TUMOR VOLUME; VERY ELDERLY;

ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA; FEMALE; HOSPITALS, TEACHING; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; MIDDLE AGED; MOROCCO; PARAFFIN EMBEDDING; PREDICTIVE VALUE OF TESTS; PREVALENCE; TUMOR BURDEN; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

MLCS; MLOWN;

EID: 84870490659     PISSN: None     EISSN: 17461596     Source Type: Journal    
DOI: 10.1186/1746-1596-7-170     Document Type: Article

References (32)

1. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature 2000, 406:747-752. 10.1038/35021093, 10963602.
2. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001, 98:10869-10874. 10.1073/pnas.191367098, 58566, 11553815.
3. Sorlie T. Molecular portraits of breast cancer: tumour subtypes as distinct disease entities. Eur J Cancer 2004, 40:2667-26675. 10.1016/j.ejca.2004.08.021, 15571950.
4. Aleix P, Parker JS, Olga K, Cheng F, Chad L, Herschkowitz JI, Xiaping H, Perou CM. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res 2010, 12:R68. 10.1186/bcr2635, 3096954, 20813035.
5. Bhargava R, Striebel J, Beriwal S, et al. Prevalence, morphologic features and proliferation indices of breast carcinoma molecular classes using immunohistochemical surrogate markers. Int J Clin Exp Pathol 2009, 2:444-455. 2655155, 19294003.
6. Tang P, Wang J, Bourne P. Molecular classifications of breast carcinoma with similar terminology and different definitions: are they the same?. Hum Pathol 2008, 39:506-513. 10.1016/j.humpath.2007.09.005, 18289638.
7. Pathology and genetics of tumours of the breast and female genital organs, world health organization classification of tumours 2003, Lyon: IARC Press, Tavassoli F, Devilee P.
8. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow up. Histopathology 1991, 19(5):403-410. 10.1111/j.1365-2559.1991.tb00229.x, 1757079.
9. American Joint Committee on Cancer AJCC cancer staging handbook 2010, http://www.springer.com/medicine/surgery/cancer+staging?SGWID=0-40654-0-0-0, Last accessed on 14/1/2011, American Joint Committee on Cancer.
10. Wolff AC, Elizabeth M, Hammond H, et al. Guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. American Society of Clinical Oncology/College of American Pathologists. J Clin Oncol 2007, 25:118-145.
11. Prat A, Ellis MJ, Perou CM. Practical implications of gene-expression-based assays for breast oncologists. Nat Rev Clin Oncol 2011, 9(1):48-57. 10.1038/nrclinonc.2011.178, 22143140.
12. Arvydas L, Aida L, Valerijus O, Darius D, Sonata J, Juozas L. Immunohistochemistry profiles of breast ductal carcinoma: factor analysis of digital image analysis data. Diagn Pathol 2012, 7:27. 10.1186/1746-1596-7-27, 3319425, 22424533.
13. Ross JS, Fletcher JA, Bloom KJ, et al. Targeted therapy in breast cancer. Mol Cell Proteomics 2004, 3:379-398. 10.1074/mcp.R400001-MCP200, 14762215.
14. Junichi K, Takoya M, Takanori I, et al. The prevalence of intrinsic subtypes and prognosis in breast cancer patients of different races [abstract]. Breast 2007, 16(Suppl 2):S72-S77.
15. Ciardiello F, Troiani T, Caputo F, De Laurentiis M, Tortora G, Palmieri G, De Vita F, Diadema MR, Orditura M, Colantuoni G, et al. Phase II study of gefitinib in combination with docetaxel as first-line therapy in metastatic breast cancer. Br J Cancer 2006, 94:1604-1609. 2361320, 16685276.
16. Baselga J, Albanell J, Ruiz A, Lluch A, Gascon P, Guillem V, Gonzalez S, Sauleda S, Marimon I, Tabernero JM, et al. Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer. J Clin Oncol 2005, 23:5323-5333. 10.1200/JCO.2005.08.326, 15939921.
17. Tsutsui S, Kataoka A, Ohno S, Murakami S, Kinoshita J, Hachitanda Y. Prognostic and predictive value of epidermal growth factor receptor in recurrent breast cancer. Clin Cancer Res 2002, 8:3454-3460.
18. Tsuda H, Morita D, Kimura M, Shinto E, Ohtsuka Y, Matsubara O, Inazawa J, Tamaki K, Mochizuki H, Tamai S, Hiraide H. Correlation of KIT and EGFR overexpression with invasive ductal breast carcinoma of the solid-tubular subtype, nuclear grade 3, and mesenchymal or myoepithelial differentiation. Cancer Sci 2005, 96:48-53. 10.1111/j.1349-7006.2005.00009.x, 15649255.
19. Walker RA, Dearing SJ. Expression of epidermal growth factor receptor mRNA and protein in primary breast carcinomas. Breast Cancer Res Treat 1999, 53:167-176. 10.1023/A:1006194700667, 10326794.
20. Kobayashi S, Boggon TJ, Dayaram T, Janne PA, Kocher O, Meyerson M, Johnson BE, Eck MJ, Tenen DG, Halmos B. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005, 352:786-792. 10.1056/NEJMoa044238, 15728811.
21. Kristensen VN. Divide and conquer: the genetic basis of molecular sub classification of breast cancer. EMBO Mol Med 2011, 3:183-185. 10.1002/emmm.201100128, 3377072, 21394915.
22. Gomes DS, Débora B, Porto SS, Helenice G. Lobular neoplasia: frequency and association with other breast lesions. Diagn Pathol 2011, 6:74. 9 August 2011, 10.1186/1746-1596-6-74, 3170574, 21827679.
23. Abdel-Fatah TM, Powe DG, Hodi Z, Lee AH, Reis-Filho JS, Ellis IO. High frequency of coexistence of columnar cell lesions, lobular neoplasia, and low grade ductal carcinoma in situ with invasive tubular carcinoma and invasive lobular carcinoma. Am J Surg Pathol 2007, 31:417-426. 10.1097/01.pas.0000213368.41251.b9, 17325484.
24. Bratthauer GL, Tavassoli FA. Lobular intraepithelial neoplasia: previously unexplored aspects assessed in 775 cases and their clinical implications. Virchows Arch 2002, 440:134-138. 10.1007/s00428-001-0541-5, 11964042.
25. Peng XH, Karna P, O'Regan RM, Liu X, Naithani R, Moriarty RM, Wood WC, Lee HY, Yang L. Down-regulation of inhibitor of apoptosis proteins by deguelin selectively induces apoptosis in breast cancer cells. Mol Pharmacol 2007, 71(1):101-111. 3132577, 17035597.
26. Bockbrader KM, Tan M, Sun Y. A small molecule Smac-mimic compound induces apoptosis and sensitizes TRAIL- and etoposide-induced apoptosis in breast cancer cells. Oncogene 2005, 24(49):7381-7388. 10.1038/sj.onc.1208888, 16044155.
27. Yutao Z, Jianhua Z, Yun T, Feng L, Hongyuan Z, Bofang P, Chifeng Z, Rong F. X-linked inhibitor of apoptosis positive nuclear labeling: a new independent prognostic biomarker of breast invasive ductal carcinoma. Diagn Pathol 2011, 6:49. 10.1186/1746-1596-6-49, 3126758, 21645409.
28. Matter K, Balda MS. Signaling to and from tight junctions. Nat Rev Mol Cell Biol 2003, 4:225-236.
29. Tsukita S, Furuse M. Occludin and claudins in tight-junction strands: leading or supporting players?. Trends Cell Biol 1999, 9:268-273. 10.1016/S0962-8924(99)01578-0, 10370242.
30. Tsukita S, Furuse M, Itoh M. Multifunctional strands in tight junctions. Nat Rev Mol Cell Biol 2001, 2:285-293. 10.1038/35067088, 11283726.
31. Santos PB, Zanetti JS, Silva AR, Beltrão EIC. Beta 1 integrin predicts survival in breast cancer: a clinicopathological and immunohistochemical study. Diagnostic Pathology 2012, 7:104. 10.1186/1746-1596-7-104, 22894137.
32. MariadelasMercedes N, Fernando P, Florencia P, Néstor L, Hugo K, Silvana N, Alejandro G, Alejandra A, Boris E, Valeria D, Miembro de la Carrera de Investigador del Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET) Immunohistochemical characterization of neoplastic cells of breast origin. Diagn Pathol 2012, 7:73. 10.1186/1746-1596-7-73, 3468373, 22726568, Miembro de la Carrera de Investigador del Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET).